Document is current
Any future updates will be listed below
-
Authors
Abolhassani, Ayda
Alawathurage, T. Madhusankha
Schmidt, Axel
Brand, Fabian
Kilarski, Laura L.
Altmann, Heidi
Dahl, Edgar
Frank, Sandra
Göpel, Siri
Hanses, Frank
Hellmuth, Johannes Christian
Herr, Christian
Kaasch, Achim J.
Kobbe, Robin
Konik, Margarethe Justine
Pink, Isabell
Römmele, Christoph
Rupp, Jan
Scheer, Christian S.
Schneider, Marc A.
Stellbrink, Christoph
Stubbe, Hans Christian
Tepasse, Phil-Robin
Teufel, Andreas
Vadász, István
Vehreschild, Maria J. G. T.
Witzenrath, Martin
Anton, Gabriele
Bröhl, Isabel
Herold, Susanne
Illig, Thomas
Jiru-Hillmann, Steffi
Krawitz, Peter
Mitrov, Lazar
Philipsen, Alexandra
Pütz, Sina M.
Noethen, Markus M.
Nuernberg, Peter
Reese, Jens-Peter
Riess, Olaf
Schreiber, Stefan
Schultze, Joachim
Steinbeis, Fridolin
Vehreschild, J. Janne
Wildberg, Christian
Ludwig, Kerstin U.
Schulte, Eva C.
-
Funding
Funding for this research was provided by:
Rheinische Friedrich-Wilhelms-Universität Bonn
- License Information
-
More Information
Article History
Received: 7 November 2025
Accepted: 23 December 2025
First Online: 23 January 2026
Declarations
:
: SH reports consulting fees from AstraZeneca (Vaxzevria Vaccine Program Advisory Board) and Janssen (RSV Vaccine Program Advisory Board).
